We comprehensively analyzed the changes in the expression of SLC transporters associated with glutaminolysis metabolic flux using TCGA data and found that the aberrant expression of SLCs is a common feature of KRAS-mutant CRC, indicating that metabolite transporters may be a novel biomarker as well as a potential therapeutic target in KRAS-mutant CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.